Objective: To determine the association between obesity and prostate cancer in Japanese recurrence after primary treatment with radical prostatectomy. Methods: The subjects were 173 Japanese patients with prostate cancer who had been treated with radical prostatectomy at Chiba University Hospital between April 1997 and March 2007. Clinicopathological characteristics and biochemical recurrence outcomes after radical prostatectomy were compared between the three body mass index cohorts. Results: Mean body mass index was 23.4 kg/m 2 with a standard deviation of 2.4, and mean follow-up period was 37.4 months. Operative time was longer and estimated blood loss was much more in obese patients. Patients with pT3 had significantly higher serum prostatespecific antigen, total cholesterol levels, Gleason's sum and positive of surgical margin than pT2 patients. Recurrence rate was significantly higher in the 26.5 kg/m 2 and hyperlipidemia groups in pT3 patients. Conclusions: Obesity is an independent predictor of disease recurrence in Japanese patients with pT3 prostate cancer who underwent radical prostatectomy. Obese patients who underwent radical prostatectomy require vigilant follow-up care.
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer in men in Western Europe and North America. In addition, incidence of PCa is rapidly increasing in Japan. Radical prostatectomy (RP) is the first-line treatment for organconfined PCa. The goal of RP is the complete removal of intact prostate. Several prognostic factors have been proposed for biochemical recurrence or survival following RP such as the pre-operative prostate-specific antigen (PSA) level and pathological features, including the Gleason sum and a positive surgical margin (1) . The relationship of obesity to PCa risk is controversial, with some studies indicating that obesity is associated with a decreased incidence of PCa and other studies suggesting an increased incidence of PCa and worse PCa survival among obese men (2 -4) . Body mass index (BMI) is a useful index to evaluate obesity, calculated as weight in kilograms divided by height in meter squared (kg/m 2 ). The prevalence of obesity (BMI . 30%) is 30% in the USA in 2000 (5) . According to OECD health data in 2005, the prevalence of obesity (BMI . 30%) is only 3% in Japan. Recently, multi-institutional studies have reported greater recurrence rates among obese patients after RP in Western Europe and North America (6, 7) . However, only one study has been evaluated the independent relationship of BMI to PCa recurrence after treatment with RP in Japanese (8) . The mechanism by which obesity is related to the incidence and prognosis of PCa is still unclear. RP is technically more difficult in obese men; therefore, surgical margin is highly positive during surgical dissection of the prostate in obese men. The other possible mechanism is the balance of hormonal concentration (i.e. testosterone, estrogen, insulin and leptin) (9 -11) . Late-onset hypogonadism has been reported to be related to obesity, and a low testosterone level has been suggested to relate to poor pathological features (12, 13) . We already reported that lower pre-treatment total testosterone level appears to be predictive of extra-prostatic disease in patients with localized PCa (14) . On the other hand, high BMI independently contributes to PSA recurrence but the total testosterone level does not (8) . In this study, we sought to evaluate the independent relationship of obesity to PCa recurrence after treatment with RP in Japanese. Table 1 . BMI was calculated on all patients of whom height and weight information was recorded pre-operatively. Patients' height and weight were used to calculate BMI using the following formula: BMI ¼ weight (kilograms)/height (meters) (2) . There was no patient whose BMI was over 30 kg/m 2 , BMI was used to categorize patients into two BMI groups according to the Japan Society for the Study of Obesity (JASSO) classification of obesity: obese (BMI ¼ 25 -30 kg/ m 2 ) and normal (BMI , 25 kg/m 2 ). Blood samples were taken in the morning. Serum PSA, testosterone and LH level were measured by ARCHITECT (Abbott Laboratories, Abbott Park, IL, USA). Serum totalcholesterol level was measured by KL 'KOKUSAI' (Sysmex, Hyougo, Japan).
PATIENTS AND METHODS
Staging was based on the 1997 TNM classification. All patients underwent retropubic RP as the first-line treatment by multiple surgeons. In our institution, if a less experienced surgeon performs an RP, a more experienced surgeon serves as the first assistant during surgery. Pathology of PCa was evaluated by whole-mount step sectioning. Organ-confined disease was defined as cancer that had no capsular penetration, seminal vesicle (SV) involvement or pelvic lymph node (LN) involvement. Non-organ-confined cancer (pT3 -pT4, N1; extra-prostatic disease) was defined as cancer with capsular penetration or involvement of SVs or pelvic LNs. Biochemical recurrence of PCa was defined as two consecutive increases in serum PSA by .0.2 ng/ml.
Statistical significance was examined using x 2 test, MannWhitney's U-test and the log-rank test. Multivariate analysis was performed using a logistic regression model and a Cox proportional hazards model. Biochemical-recurrence-free survival rate was calculated using the Kaplan -Meier method. All statistical tests were two-sided and a P value ,0.05 was considered to indicate significance. All statistical analyses were performed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). 2 ). Age, PSA level and pathological factors (Gleason's sum, pathological stage, LN positive, surgical margin, organ confined and SV involvement) did not show significant correlation with BMI. As the peri-operative factor, operative time was longer (P ¼ 0.002) and estimated blood loss was much more (P ¼ 0.003) in obese patients. As the obese factors, obese patients had significantly higher serum total cholesterol levels (P ¼ 0.009) than normal. As the hormonal factors of patients between the two BMI groups, obese patients had significantly higher serum LH levels (P ¼ 0.013) than normal. On the other hand, the serum testosterone level did not show significant correlation with BMI. Table 2 shows univariate and multivariate analyses of predictors of extra-prostatic disease (pT2 vs. pT3) according to the logistic regression model. PSA level [odds ratio (OR) ¼ 1.049, 95% confidence interval (CI): 1.006 -1.094], pathological Gleason score (2 -6 or 7 -10) (OR ¼ 6.097, 95% CI: 2.246 -16.553) and testosterone level (OR ¼ 0.711, 95% CI: 0.549 -0.920) were independently significant. Total-cholesterol level was the significant predictor of extraprostatic disease in univariate analysis, but was not in multivariate analysis. BMI and LH levels did not show significant difference in univariate and multivariate analyses. The incidence of positive surgical margins was not significant in two BMI groups (BMI , 25 vs. BMI 25 kg/m 2 ). Disease-free survival was estimated using the KaplanMeier method and compared among several patient groups. Biochemical recurrence was occurred in 50 patients. No patients died of PCa and a total of one patient died of other cancer. There was no significant difference for a recurrence between the two BMI groups (BMI , 25 vs. BMI 25 kg/m 2 ) in all cases (data not shown).
RESULTS

Mean
We performed more detailed subgroup analysis about BMI and post-operative recurrence rate of the PCa. Moreover, we analyzed about hyperlipidemia and postoperative recurrence rate of the PCa. Also, we defined serum cholesterol level 220 mg/dl or taken cholesterol-lowering drugs as hyperlipidemia in this study. There was no significant difference for a recurrence between the BMI and
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Implications of BMI after radical prostatectomy hyperlipidemia in pT2 cases (data not shown). Also, when we analyzed more than pT3 cases, recurrence rate was significantly higher in the 26.5 kg/m 2 (P ¼ 0.024) and hyperlipidemia groups (P ¼ 0.005) (Fig. 1a and b) . Table 3 0.981 -4.007) were significant independent predictors of PSA failure. BMI, serum total cholesterol, serum testosterone and serum LH did not appear to affect biochemical recurrence. Table 4 shows the factors that were predictive of diseasefree survival in both univariate and multivariate analyses using Cox's proportional hazards analysis in pT3 cases. In univariate analysis, PSA (HR ¼ 1.050, 95% CI: 1.040 -1.084), operation time (HR ¼ 1.009, 95% CI: 1.001 -1.017), hyperlipidemia group (HR ¼ 1.050, 95% CI: 1.366 -9.674) and high BMI (HR ¼ 3.321, 95% CI: 0.400 -1.526) were significant predictors of PSA failure. In multivariate analysis, PSA (RR ¼ 1.047, 95% CI: 1.024 -1.070) was the only significant independent predictor of PSA failure. Gleason score, serum total cholesterol, serum testosterone and serum LH did not appear to affect biochemical recurrence.
DISCUSSION
The prevalence of obesity (BMI 30 kg/m 2 ) in Japanese adults has been quite low (1 -3%) compared not only with western countries, but also with some Asian and other countries (15, 16) . Similarly, none of the patients have BMI of .30 kg/m 2 in this study. The latest prevalence of obesity for the time period 1991 -95 was only 2.0% in Japan; on the other hand, .30% of the adult population are obese in the USA, i.e. almost 10 times higher than the figures reported in Japan (17) . WHO expert consultation concluded that Asians generally have a higher percentage of body fat than white people of the same age, sex and BMI. Also, the proportion of Asian people with risk factors for type 2 diabetes and cardiovascular disease is substantial even below the existing WHO BMI cut-off point of 25 kg/m 2 . From a public health standpoint and the need for effective strategies for the primary prevention of chronic obesity-associated diseases, decreasing the fraction of the population with BMI values of 25-29.9 kg/m 2 is important for reducing the risk of such diseases in the Japanese population (17) .
Obesity is associated with a greater risk of death from PCa and a greater risk of progression after RP (7 -11,18,19) . BMI was significantly and positively related to increased odds of capsular incision. Anymore, Freedland et al. (20) reported that obesity affected the Gleason score, positive surgical margin, capsular invasion and LN metastasis. However, only one study have been evaluated the independent relationship of BMI to PCa recurrence after treatment with RP in Japanese (8). They could not find significant correlation with BMI for any adverse pathological features, including the surgical margin similar to our study. The 
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Implications of BMI after radical prostatectomy degree to which technical difficulty in performing RP in obese men contributes to the increased risk of progression after RP in obese men, as observed in multiple prior studies, remains to be determined (7, 8, 20, 21) . RP is technically more difficult in obese men, which results in a greater likelihood of a less than technically ideal operation (22) . Moreover, these technical challenges are apparent regardless of the method of surgical approach. When the prostate is approached through a retropubic incision, the excess transabdominal fat makes access to the prostate more difficult. Intra-abdominal adiposity can similarly affect access in the laparoscopic approach. Although perineal prostatectomy avoids both transabdominal and intra-abdominal fat, obese men are still at increased risk of positive surgical margins through a perineal approach (23) . It has also been shown that obese men have larger prostates and these in turn can be difficult to remove through a perineal approach, thereby resulting in an iatrogenic-positive surgical margin.
One of the possible mechanisms, steroid hormones, including testosterone, or obesity-related cytokines such as adiponectin, leptin, insulin and IGF-1 were proposed to be candidates (24 -26) . We already reported that lower pre-treatment total testosterone level appears to be predictive of extra-prostatic disease in patients with localized PCa (14). Hoffman et al. (27) reported that low serum-free testosterone is a marker of more aggressive disease, but they noted no significant differences based on total testosterone. Massengill et al. (28) found that total testosterone was a predictor of extra-prostatic disease in univariate and multivariate analyses of localized PCa patients. Thus, the available evidence suggests that pre-treatment total testosterone level is useful in the management of localized PCa. Obesity in men is associated with a decline in total plasma testosterone and free testosterone, which parallels body fat mass (29) . However, we could not find any relationship between the total testosterone level and BMI in this study. The mechanism of the relationship between serum testosterone and prognosis of PCa remains to be elucidated, and attempts have been made to define the influence of the prostate on serum hormone levels. The major pathogenic factors suggested as being responsible for testosterone reduction in obesity are the decrease in the binding capacity of sex hormone-binding globulin (SHBG), the reduction of LH pulse amplitude and hyperestrogenemia. Alternatively, an altered metabolism or an excess of fat-derived hormonal products may cause an impairment of testicular interstitial function. Bioavailable testosterone is affected by SHBG level, which is influenced by aging and obesity itself (30) . Adiposity-related cytokines such as adiponectin and leptin might influence cancer aggressiveness following surgery as recently reported (26, 31, 32) . Adiponectin is an adipokine with insulin-sensitizing properties which is inversely associated with obesity and has been inversely related to the incidence of several hormonally dependent cancers. Freedland et al. (31) shown that lower adiponectin levels were associated with advanced pathological stage or higher Gleason score at prostatectomy, depending on the BMI of the patient. On the other hand, Sher et al. reported that there was no association between biopsy Gleason score and adiponectin, in patients who had undergone RP, and lower adiponectin was independently associated with high-grade PCa. Anymore, they tested for a statistical interaction between BMI and adiponectin and did not find one (32) . Nevertheless, additional epidemiological and laboratory work is necessary to elucidate the role adiponectin plays in prostate oncogenesis.
Leptin, the obese gene product secreted from adipocytes, circulates in plasma at concentrations that parallel the amount of fat reserves and controls adiposity by modulating food intake and energy metabolism. It has been demonstrated that leptin receptors are present in testicular tissue. Serum leptin levels are inversely correlated with testosterone and it has been recently proposed that testosterone may regulate obese gene expression (33) . In our result, obese patients (BMI 25 kg/m 2 ) had significantly higher serum LH levels (P ¼ 0.013) than normal BMI patients. The impaired androgen response to LH stimulus was due to a defect in the enzymatic conversion of 17-OH-progesterone to testosterone, which was disclosed by a leptin-related increase in 17-OH-progesterone to testosterone ratio (34). Isidori et al. suggest that leptin may be an important contributor to the pathogenesis of reduced androgens in obese men.
Sivaprasad et al. (35) reported that cholesterol-lowing drugs (i.e. statins) induce apoptosis and inhibit the proliferation of PCa cell lines in vitro. However, despite provocative laboratory evidence, epidemiological studies of hyperlipidemia and PCa are inconclusive. Magura et al. (36) suggested that hypercholesterolemia increases the risk of PCa. Also, Bravi et al. (37) showed a significant increased risk of PCa among hyperlipidemia patients (OR ¼ 1.51). Murtola et al. (38) showed no evidence for reduced overall PCa risk among users of cholesterol-lowing drugs, but found a decreased risk of advanced cancer among users of cholesterol-lowing drugs. On the other hand, Bonovas et al. (39) reported no evidence of an association between statin use and total PCa in observational studies. The prevalence of obesity (BMI 30 kg/m 2 ) in Japanese adults is low (1 -3%) compared with western countries. Thus, there are few data regarding this relationship among Japanese subjects. In the present study, it proved the relationships among biochemical recurrence and obese after RP in Japanese patients with PCa. We would like to clarify the involvement of adiponectin, leptin and other factors in biochemical recurrence through an extended time course for both the biochemical recurrence and cancer-specific survival in the future. In our study, the recurrence rate was significantly higher in the hyperlipidemia group than in pT3 cases. On the other hand, in pT2 cases, there were no significant differences in recurrence rate between all PCa cases and cases with hyperlipidemia. Hammarsten and Högstedt (40) found that lower HDL levels were associated with higher Gleason scores in patients with PCa, suggesting that hyperlipidemia may be associated with PCa progression.
In conclusion, obesity is an independent predictor of disease recurrence in Japanese patients with pT3 PCa who underwent RP that was similar to Western Europe and North America PCa patients. One of the reasons is that RP is technically more difficult in obese patients, which results in a greater likelihood of a less than technically ideal operation. As a result, obese individuals who underwent RP require vigilant follow-up care. Further investigation must be needed to evaluate the efficacy of other treatment modality in obese patients with PCa, as well as to clarify how PCa recurrence affects survival in obese patients.
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